PDCD1 and hypothyroidism: The results demonstrated that toripalimab plus GP prolongs the PFS compared with GP alone in recurrent or metastatic NPC but maintains a manageable safety profile.[7] The current NCCN guidelines recommend anti-PD-1 monoclonal antibody as a subsequent-line treatment for recurrent or metastatic NPC.[35] However, side effects associated with PD-1/PD-L1 blockade have been characterized by a distinct range of toxic effects, termed immune-related AEs, including rash, colitis, hepatitis, and hypothyroidism.